Showing 15,081 - 15,100 results of 47,188 for search '(( 50 ((a decrease) OR (we decrease)) ) OR ( 5 ((wt decrease) OR (mean decrease)) ))', query time: 0.95s Refine Results
  1. 15081

    Image_3_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif by Majd Jawad (12157533)

    Published 2022
    “…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
  2. 15082

    Image_1_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif by Majd Jawad (12157533)

    Published 2022
    “…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
  3. 15083

    Image_2_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif by Majd Jawad (12157533)

    Published 2022
    “…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
  4. 15084

    Table_2_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.docx by Majd Jawad (12157533)

    Published 2022
    “…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
  5. 15085

    Table_1_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.docx by Majd Jawad (12157533)

    Published 2022
    “…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
  6. 15086

    Study flow and included patients. by Chung-Yeh Chuang (15285925)

    Published 2023
    “…In the multivariate analysis, being underweight (adjust OR [aOR], 3.80, compared to normoweight; 95% CI, 1.23–11.7) and lower maximal inspiratory airway pressure (aOR per one cmH<sub>2</sub>O decrease, 1.05; 95% CI 1.00–1.09) remained significantly associated with extubation failure.…”
  7. 15087

    Weaning parameters before planned extubation. by Chung-Yeh Chuang (15285925)

    Published 2023
    “…In the multivariate analysis, being underweight (adjust OR [aOR], 3.80, compared to normoweight; 95% CI, 1.23–11.7) and lower maximal inspiratory airway pressure (aOR per one cmH<sub>2</sub>O decrease, 1.05; 95% CI 1.00–1.09) remained significantly associated with extubation failure.…”
  8. 15088

    S1 Data - by Chung-Yeh Chuang (15285925)

    Published 2023
    “…In the multivariate analysis, being underweight (adjust OR [aOR], 3.80, compared to normoweight; 95% CI, 1.23–11.7) and lower maximal inspiratory airway pressure (aOR per one cmH<sub>2</sub>O decrease, 1.05; 95% CI 1.00–1.09) remained significantly associated with extubation failure.…”
  9. 15089

    Baseline characteristics of enrolled patients. by Chung-Yeh Chuang (15285925)

    Published 2023
    “…In the multivariate analysis, being underweight (adjust OR [aOR], 3.80, compared to normoweight; 95% CI, 1.23–11.7) and lower maximal inspiratory airway pressure (aOR per one cmH<sub>2</sub>O decrease, 1.05; 95% CI 1.00–1.09) remained significantly associated with extubation failure.…”
  10. 15090

    Table_2_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  11. 15091

    Table_6_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  12. 15092

    Table_3_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  13. 15093

    Table_8_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  14. 15094

    Table_7_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  15. 15095

    Table_4_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  16. 15096

    Table_9_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  17. 15097

    Table_1_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  18. 15098

    Data_Sheet_5_Personalized surgical planning for coronary bypass graft configurations using patient-specific computational modeling to avoid flow competition in arterial grafts.XLSX by Krish Chaudhuri (13866956)

    Published 2023
    “…The use of the computational models led to a significant decrease in the selection of unsatisfactory grafting configurations when surgeons employed “anaortic” (21.25% (17/80) vs. 1.25% (1/80), P < 0.001) but not “aortic” techniques (5% (4/80) vs. 0% (0/80), P = 0.64). …”
  19. 15099

    Data_Sheet_5_Personalized surgical planning for coronary bypass graft configurations using patient-specific computational modeling to avoid flow competition in arterial grafts.XLSX by Krish Chaudhuri (13866956)

    Published 2023
    “…The use of the computational models led to a significant decrease in the selection of unsatisfactory grafting configurations when surgeons employed “anaortic” (21.25% (17/80) vs. 1.25% (1/80), P < 0.001) but not “aortic” techniques (5% (4/80) vs. 0% (0/80), P = 0.64). …”
  20. 15100